Cyclo(Arg-Gly-Asp-D-Phe-Cys) (TFA)

• UNSPSC Description:

  Cyclo(Arg-Gly-Asp-D-Phe-Cys) (Cyclo RGDfC) TFA, a cyclic RGD peptide which has high affinity to αvβ3, can disrupt cell integrin interactions. Cyclo(Arg-Gly-Asp-D-Phe-Cys) TFA inhibits pluripotent marker expression in embryonic stem cells (ESCs) and the tumorigenic potential of mESCs in vivo. Cyclo(Arg-Gly-Asp-D-Phe-Cys) TFA can be used in the research of tumors[1].

• Target Antigen:

  Integrin

• Type:

  Peptides

• Related Pathways:

  Cytoskeleton

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/cyclo-arg-gly-asp-d-phe-cys-tfa.html

• Purity:

  98.59

• Solubility:

  H2O : 13.3 mg/mL (ultrasonic;warming)

• Smiles:

  O=C([C@@H](CC1=CC=CC=C1)NC([C@H](CC(O)=O)NC(CNC2=O)=O)=O)N[C@@H](CS)C(N[C@H]2CCCNC(N)=N)=O.OC(C(F)(F)F)=O

• Molecular Weight:

  692.66

• References & Citations:

  [1]Hazenbiller O, et al. Reduction of pluripotent gene expression in murine embryonic stem cells exposed to mechanical loading or Cyclo RGD peptide. BMC Cell Biol. 2017 Nov 14;18(1):32.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light, under nitrogen)

• Clinical Information:

  No Development Reported